# ClinicalTrials.gov record NCT02176382

> PeptideScanner retained ClinicalTrials.gov record NCT02176382 at 2026-07-30T20:06:10.499Z. Its registry update date was 2021-02-09, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct02176382-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-02-09
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02176382-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct02176382-teriparatide-v1.json
- Content SHA-256: `8e0fbf9b4519bc3fcdcc547c76acec92138f19687a97cb8b100fbaa7cf23767b`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT02176382 ([`ctg-observation-nct02176382-2021-02-09-fbc79a2e2fb4`](#source-ctg-observation-nct02176382-2021-02-09-fbc79a2e2fb4))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02176382 at 2026-07-30T20:06:10.499Z. Its registry update date was 2021-02-09, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct02176382-2021-02-09-fbc79a2e2fb4`](#source-ctg-observation-nct02176382-2021-02-09-fbc79a2e2fb4))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02176382 at 2026-07-30T20:06:10.499Z. Its registry update date was 2021-02-09, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct02176382-2021-02-09-fbc79a2e2fb4`](#source-ctg-observation-nct02176382-2021-02-09-fbc79a2e2fb4))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02176382-2021-02-09-fbc79a2e2fb4`](#source-ctg-observation-nct02176382-2021-02-09-fbc79a2e2fb4))

## Sources

<a id="source-ctg-observation-nct02176382-2021-02-09-fbc79a2e2fb4"></a>
- **ClinicalTrials.gov record NCT02176382 · retained source version 2021-02-09:fbc79a2e2fb4f31f13993de0a034521b7868803283ac9a00c503fb8a99148806** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02176382) (`ctg-observation-nct02176382-2021-02-09-fbc79a2e2fb4`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02176382." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct02176382-teriparatide-v1.json SHA-256: 8e0fbf9b4519bc3fcdcc547c76acec92138f19687a97cb8b100fbaa7cf23767b.